Discover the top 25 companies transforming the companion diagnostics market, including F. Hoffmann-La Roche Ltd., Agilent Technologies, Inc., Qiagen, and other industry leaders. Backed by a market projected to grow from $7.5B to $13.6B by 2029 at a CAGR of 12.6%, this analysis highlights competitive strengths, breakthrough innovations, and strategic moves shaping the future of the industry. Access the full market research report for deeper insights.
Download PDF Brochure:“Click Here”
Spotlights on the Industry’s Top Companion Diagnostics Companies
F. Hoffmann-La Roche Ltd.
F. Hoffmann-La Roche Ltd is a dominant global leader in the in vitro diagnostics market, primarily through its Roche Diagnostics division. The company provides an extensive array of integrated solutions, including molecular diagnostics, tissue diagnostics, and centralized laboratory testing, anchored by its renowned cobas series platforms. Roche’s strategic focus on personalized healthcare and rapid infectious disease testing is supported by continuous innovation, such as the development of expanded point-of-care panels and high-efficiency diagnostic systems that improve laboratory workflows and medical decision-making.
Agilent Technologies, Inc.
Agilent Technologies, Inc. is a premier global provider of instruments, software, services, and consumables for laboratories, with a significant presence in the life sciences and diagnostics sectors. Spun off from Hewlett-Packard in 1999, the company focuses on providing critical insights and measurement tools for applications in pharmaceuticals, clinical diagnostics, and environmental testing. Agilent’s portfolio includes advanced technologies for gas and liquid chromatography, mass spectrometry, and immunohistochemistry, enabling healthcare providers and researchers to improve lab efficiency and diagnostic accuracy.
Qiagen
Qiagen is a major global player in molecular diagnostics and life sciences research, specializing in technologies that extract, purify, and analyze genetic materials such as DNA and RNA. Headquartered in the Netherlands, the company provides comprehensive “Sample to Insight” solutions, including automated PCR systems like QIAstat-Dx and digital PCR platforms like QIAcuity. Qiagen’s commitment to innovation supports advances in personalized medicine, oncology diagnostics, and infectious disease detection, serving a diverse customer base across clinical, academic, and pharmaceutical sectors.
Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc. is the world leader in serving science, offering an unrivaled combination of innovative technologies and pharmaceutical services through industry-leading brands like Thermo Scientific and Applied Biosystems. The company provides a broad spectrum of diagnostic instruments, laboratory equipment, and clinical research solutions aimed at improving patient health through advanced diagnostics and the development of life-changing therapies. With a strong emphasis on precision medicine, Thermo Fisher leverages its vast R&D capabilities and global footprint to support complex analytical challenges in the life sciences and healthcare industries.
Abbott
Abbott is a global healthcare leader with a comprehensive diagnostics portfolio that includes core laboratory, molecular, point-of-care, and rapid testing solutions. The company is highly regarded for its scalable Alinity and ARCHITECT platforms, as well as its market-leading ID NOW rapid molecular system and i-STAT handheld blood analyzers. Abbott’s commitment to innovation is evidenced by its diverse offerings in infectious disease testing, cardiology, and routine screening, ensuring healthcare providers have access to reliable, high-throughput, and user-friendly tools to improve patient care across the clinical spectrum.
Danaher
Danaher is a global science and technology innovator committed to helping customers solve complex challenges and improving quality of life around the world. In the diagnostics sector, the company operates through prominent subsidiaries like Beckman Coulter and Cepheid, providing sophisticated instruments and software used in hospitals and clinical laboratories. Danaher’s focus on high-growth diagnostics markets, such as molecular diagnostics and clinical chemistry, is underpinned by its proprietary Danaher Business System (DBS), which drives continuous improvement in product quality, delivery, and innovation.
Guardant Health
Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through its proprietary blood tests and vast data sets. The company specializes in liquid biopsy technologies that enable early cancer detection and personalized treatment selection by analyzing circulating tumor DNA (ctDNA). By providing non-invasive diagnostic tools, Guardant Health supports clinicians in monitoring treatment response and identifying minimal residual disease, ultimately improving clinical outcomes for cancer patients throughout their treatment journey.
Illumina, Inc.
Illumina, Inc. is a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Its portfolio of next-generation sequencing (NGS) platforms, such as the NovaSeq and MiSeq series, enables large-scale genomic analysis that is essential for breakthroughs in personalized medicine and oncology. Illumina’s strategic focus on expanding the utility of genomics in clinical diagnostics is supported by its efforts to improve sequencing accessibility and provide integrated bioinformatics solutions for data interpretation.
Biomérieux
Biomérieux is a specialized global leader in in vitro diagnostics, with a strong focus on infectious disease diagnostics and industrial microbiology. The company provides integrated solutions for medical applications, including the automated VITEK system for pathogen identification and the BioFire FilmArray for rapid syndromic testing. Biomérieux’s commitment to combating antimicrobial resistance and improving public health is reflected in its high-performance diagnostic tools that enable faster, more accurate clinical decision-making for patients worldwide.
Icon PLC
Icon PLC is a world-leading clinical research organization (CRO) that provides specialized services to the pharmaceutical, biotechnology, and medical device industries. While primarily focused on clinical development, the company plays a vital role in the diagnostics market by supporting the validation and commercialization of new diagnostic tools and therapies. Icon’s global footprint and deep expertise in regulatory affairs and clinical trial management enable it to deliver integrated solutions that accelerate the delivery of medical innovations to patients.
Myriad Genetics, Inc.
Myriad Genetics, Inc. is a leading genetic testing and precision medicine company dedicated to providing actionable insights that help people take control of their health. The company specializes in developing and marketing molecular diagnostic tests for hereditary cancer risk, such as the BRACAnalysis test, and prenatal screening. Myriad Genetics focuses on integrating genetic information into routine medical practice to enable personalized treatment decisions and improve patient outcomes across various disease states.
Sysmex Corporation
Sysmex Corporation is a global leader in hematology and clinical laboratory testing, providing advanced instruments and reagents for the analysis of blood and other bodily fluids. Headquartered in Japan, the company is renowned for its high-throughput hematology analyzers and its commitment to technological innovation in areas like liquid biopsy and flow cytometry. Sysmex’s solutions aim to improve laboratory efficiency and diagnostic accuracy, contributing to better healthcare delivery and patient management on a global scale.
Almac Group
Almac Group is a global contract development and manufacturing organization (CDMO) providing a broad range of services to the pharmaceutical and biotech industries. Within the companion diagnostics space, Almac specializes in biomarker discovery, development, and validation to support personalized medicine initiatives. The company’s integrated approach enables its partners to streamline the development of targeted therapies and corresponding diagnostic tests, ensuring that the right patients receive the right treatments based on their unique molecular profiles.
Arup Laboratories
Arup Laboratories is a leading national reference laboratory and a nonprofit enterprise of the University of Utah, providing comprehensive clinical and anatomic pathology testing services. The laboratory offers an extensive menu of high-complexity tests, including molecular diagnostics and genetic testing, supporting hospitals and clinicians across the United States. Arup’s focus on academic excellence and research-driven diagnostics ensures that healthcare providers have access to the most advanced tools for accurate disease diagnosis and patient management.
Abnova Corporation
Abnova Corporation is the world’s largest antibody manufacturer, providing a vast array of high-quality antibodies and related proteins for research and diagnostic applications. Based in Taiwan, the company utilizes a high-throughput production platform to develop genomic-derived antibodies, supporting discovery in areas like cancer research and infectious diseases. Abnova’s extensive product catalog and custom antibody services make it a critical partner for laboratories and biotech companies seeking reliable reagents for diagnostic test development.
Biogenex
Biogenex is a leading developer and manufacturer of molecular pathology systems for cancer diagnosis and research. The company specializes in automated platforms for immunohistochemistry (IHC) and in situ hybridization (ISH), providing complete solutions that include instruments, reagents, and antibodies. Biogenex’s focus on precision and automation in tissue-based diagnostics enables pathologists to achieve more consistent and accurate results, facilitating better-informed clinical decisions in oncology.
Invivoscribe, Inc.
Invivoscribe, Inc. is a global leader in providing standardized reagents, tests, and bioinformatics tools for the study of hematologic malignancies and oncology. The company specializes in developing molecular diagnostic tools, including PCR-based assays and next-generation sequencing kits, used for clonality testing and minimal residual disease (MRD) monitoring. Invivoscribe’s commitment to quality and regulatory compliance ensures that its products support high-standard clinical research and routine diagnostic testing in laboratories worldwide.
Archerdx, Inc.
Archerdx, Inc., a part of Invitae, is a leading genomics company focused on democratizing personalized medicine through its innovative Anchored Multiplex PCR (AMP) technology. The company develops robust NGS-based assays for oncology, enabling the detection of gene fusions, mutations, and other genomic alterations from limited sample types. Archerdx’s platform is designed for use in local laboratories, facilitating faster turnaround times and broader access to precision diagnostics for cancer patients.
Q² Solutions
Q² Solutions is a leading global clinical trial laboratory services organization, formed as a joint venture between IQVIA and Quest Diagnostics. The company provides a comprehensive suite of laboratory services, including biomarker development, central lab testing, and companion diagnostic validation. By combining IQVIA’s clinical trial expertise with Quest’s diagnostic capabilities, Q² Solutions helps biopharmaceutical companies accelerate drug development and deliver personalized therapies through integrated, data-driven laboratory solutions.
Amoy Diagnostics Co., Ltd.
Amoy Diagnostics Co., Ltd. is a leading provider of molecular diagnostic products for personalized medicine, with a particular focus on oncology. Based in China, the company develops and manufactures high-quality PCR and NGS-based kits for the detection of critical biomarkers in various cancers. Amoy Diagnostics’ products are widely used in hospitals and laboratories globally, supporting clinicians in selecting the most effective targeted therapies and improving the management of cancer patients.
Uniogen
Uniogen is an innovative healthcare technology company specializing in the development of rapid diagnostic solutions and automated laboratory systems. The company focuses on integrating advanced sensing technologies and digital platforms to provide user-friendly tools for point-of-care and clinical laboratory testing. Uniogen’s commitment to improving diagnostic accessibility and efficiency supports healthcare providers in delivering timely and accurate care, particularly in resource-limited settings.
Asuragen, Inc.
Asuragen, Inc., a Bio-Techne brand, is a specialized molecular diagnostics company focused on developing innovative products for genetics and oncology. The company leverages its proprietary chemistries to create robust assays for challenging genomic targets, such as the FMR1 gene for Fragile X syndrome. Asuragen’s emphasis on simplifying complex molecular testing through high-quality kits and bioinformatics tools enables clinical laboratories to provide reliable results for critical patient management decisions.
Meso Scale Diagnostics, LLC
Meso Scale Diagnostics, LLC is a global leader in the development and manufacture of high-performance electrochemiluminescence (ECL) based assays and instruments for the life sciences and clinical research markets. The company’s MULTI-ARRAY technology enables highly sensitive and multiplexed detection of biomarkers in a variety of sample types. Meso Scale’s platforms are widely used in drug discovery, clinical trials, and basic research, providing scientists with reliable data for understanding disease mechanisms and evaluating therapeutic efficacy.
Creative Biolabs
Creative Biolabs is a leading service provider in the biotechnology industry, specializing in antibody discovery, engineering, and manufacturing. The company offers a wide range of custom services and high-quality reagents for diagnostic development, including monoclonal and polyclonal antibody production. Creative Biolabs’ extensive expertise in protein engineering and synthetic biology supports researchers and pharmaceutical companies in developing innovative diagnostic tools and targeted therapies for various diseases.
NG Biotech
NG Biotech is a French biotechnology company specializing in the development and manufacture of rapid, point-of-care diagnostic tests. The company focuses on innovative multiplex platforms that enable the simultaneous detection of multiple pathogens or biomarkers from a single sample, particularly in the areas of antibiotic resistance and women’s health. NG Biotech’s commitment to high-performance, user-friendly diagnostics supports healthcare professionals in making immediate clinical decisions, enhancing patient management and public health outcomes.
Download PDF Brochure:“Click Here”
